• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.

作者信息

Peters W P, Eder J P, Henner W D, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K

出版信息

J Clin Oncol. 1986 May;4(5):646-54. doi: 10.1200/JCO.1986.4.5.646.

DOI:10.1200/JCO.1986.4.5.646
PMID:3517240
Abstract

Twenty-nine patients were treated with 31 courses of high-dose combination cyclophosphamide, cisplatin, and carmustine (BCNU) with and without melphalan with autologous bone marrow support. Toxicity was dose related. The maximum tolerated dose for cyclophosphamide, cisplatin, and BCNU in this combination in mg/m2 was 5,625, 165, and 600, respectively. Further dose escalation was precluded by the development of multiple organ toxicity, including venoocclusive disease, refractory thrombocytopenia, and hypertension. Melphalan added to the three-drug combination produced excessive renal and gastrointestinal toxicity. Objective tumor regression occurred in 21 of 25 evaluable cases. The results suggest that selected alkylating agents can be combined in full or nearly full doses before nonmyelosuppressive dose-limiting toxicity precludes further escalation.

摘要

相似文献

1
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial.
J Clin Oncol. 1986 May;4(5):646-54. doi: 10.1200/JCO.1986.4.5.646.
2
High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.高剂量联合烷化剂预处理方案与自体骨髓支持：达纳-法伯癌症研究所/贝斯以色列医院的经验。
Cancer Treat Rep. 1987 Feb;71(2):119-25.
3
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.高剂量环磷酰胺、顺铂和马法兰联合自体骨髓支持：一项临床与药理学研究。
Cancer Chemother Pharmacol. 1989;23(6):377-83. doi: 10.1007/BF00435840.
4
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.大剂量联合烷化剂化疗加自体骨髓支持治疗转移性乳腺癌。
J Clin Oncol. 1986 Nov;4(11):1592-7. doi: 10.1200/JCO.1986.4.11.1592.
5
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
J Clin Oncol. 1988 Sep;6(9):1368-76. doi: 10.1200/JCO.1988.6.9.1368.
6
High-dose thiotepa alone and in combination regimens with bone marrow support.
Semin Oncol. 1990 Feb;17(1 Suppl 3):33-8.
7
Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.高剂量化疗联合自体骨髓支持作为高危、多淋巴结阳性恶性黑色素瘤辅助治疗的随机试验
J Natl Cancer Inst. 1993 Jul 7;85(13):1080-5. doi: 10.1093/jnci/85.13.1080.
8
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.在接受自体骨髓移植的难治性淋巴瘤患者中，递增剂量的米托蒽醌联合大剂量环磷酰胺、卡莫司汀和依托泊苷。
J Clin Oncol. 1994 Jan;12(1):141-8. doi: 10.1200/JCO.1994.12.1.141.
9
High-dose chemotherapy without autologous bone marrow transplantation in melanoma.黑色素瘤中不进行自体骨髓移植的大剂量化疗。
J Clin Oncol. 1986 Dec;4(12):1811-8. doi: 10.1200/JCO.1986.4.12.1811.
10
Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.IV期神经母细胞瘤患儿大剂量VP - 16持续静脉输注联合大剂量美法仑后行自体骨髓移植的I期研究
Bone Marrow Transplant. 1996 Apr;17(4):485-9.

引用本文的文献

1
Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.大剂量辅助化疗联合自体干细胞移植在局部晚期三阴性乳腺癌中的作用：一项回顾性病历审查
J Oncol. 2022 Sep 30;2022:3472324. doi: 10.1155/2022/3472324. eCollection 2022.
2
Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.非横纹肌肉瘤软组织肉瘤大剂量化疗后的自体造血干细胞移植。
Cochrane Database Syst Rev. 2013 Aug 7;2013(8):CD008216. doi: 10.1002/14651858.CD008216.pub4.
3
High-dose chemotherapy with autologous stem cell transplant for breast cancer: what have we learned 25 years later?
乳腺癌自体干细胞移植的大剂量化疗：25年后我们学到了什么？
Biol Blood Marrow Transplant. 2012 Jan;18(1):3-5. doi: 10.1016/j.bbmt.2011.10.045. Epub 2011 Dec 4.
4
The history and future of chemotherapy for melanoma.黑色素瘤化疗的历史与未来
Hematol Oncol Clin North Am. 2009 Jun;23(3):583-97, x. doi: 10.1016/j.hoc.2009.03.006.
5
Stem-cell transplantation for the treatment of advanced solid tumors.干细胞移植治疗晚期实体瘤。
Springer Semin Immunopathol. 2004 Nov;26(1-2):31-56. doi: 10.1007/s00281-004-0160-8. Epub 2004 Sep 11.
6
High-dose chemotherapy with autologous stem cell rescue in breast cancer.乳腺癌的大剂量化疗联合自体干细胞救援
Breast Cancer Res Treat. 1996;37(3):277-89. doi: 10.1007/BF01806509.
7
Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies.抗肿瘤烷化剂：体外交叉耐药性和间接敏感性研究
Cancer Chemother Pharmacol. 1993;33(2):113-22. doi: 10.1007/BF00685328.
8
Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions.
Cancer Chemother Pharmacol. 1994;35(1):59-63. doi: 10.1007/BF00686285.
9
High-dose therapy with stem cell support in solid tumors.实体瘤中采用干细胞支持的大剂量疗法。
Med Oncol. 1994;11(2):53-62. doi: 10.1007/BF02988831.
10
High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.高剂量环磷酰胺、顺铂和马法兰联合自体骨髓支持：一项临床与药理学研究。
Cancer Chemother Pharmacol. 1989;23(6):377-83. doi: 10.1007/BF00435840.